These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20050881)

  • 1. Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopenia.
    Pohlen M; Sargin B; Zicholl S; Bisping G; Müller-Tidow C; Berdel WE; Mesters R; Koschmieder S
    Eur J Haematol; 2010 Apr; 84(4):362-4. PubMed ID: 20050881
    [No Abstract]   [Full Text] [Related]  

  • 2. Romiplostim: an alternative treatment option besides rituximab for the management of steroid refractory idiopathic thrombocytopenic purpura.
    Kapoor S
    J Thromb Thrombolysis; 2009 May; 27(4):453. PubMed ID: 18438700
    [No Abstract]   [Full Text] [Related]  

  • 3. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
    Veneri D; Soligo L; Pizzolo G; Ambrosetti A
    Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
    Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
    Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.
    Yassa G; Shakir AR; Jagarlamudi K; Yassa AE
    J Oncol Pharm Pract; 2021 Jan; 27(1):253-257. PubMed ID: 32611269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment.
    Tagariello G; Sartori R; Radossi P; Maschio N; Risato R; Stasi R
    Br J Haematol; 2012 Apr; 157(2):256-8. PubMed ID: 22111882
    [No Abstract]   [Full Text] [Related]  

  • 7. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
    Shinohara K; Kambara N
    Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment.
    Ignatova AA; Demina IA; Ptushkin VV; Khaspekova SG; Shustova ON; Pankrashkina MM; Ryabykh AA; Obydennyi SI; Strelkova OS; Polokhov DM; Seregina EA; Poletaev AV; Ataullakhanov FI; Kireev II; Mazurov AV; Maschan AA; Novichkova GA; Panteleev MA
    Br J Haematol; 2019 Oct; 187(2):e38-e42. PubMed ID: 31422582
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531).
    Pullarkat VA; Gernsheimer TB; Wasser JS; Newland A; Guthrie TH; de Wolf JT; Stewart R; Berger D
    Am J Hematol; 2009 Aug; 84(8):538-40. PubMed ID: 19569197
    [No Abstract]   [Full Text] [Related]  

  • 10. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
    D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
    Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
    [No Abstract]   [Full Text] [Related]  

  • 11. Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim.
    Bussel JB; Wang X; Lopez A; Eisen M
    Hematology; 2016 May; 21(4):257-62. PubMed ID: 26251926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports.
    Gilreath JA; Wei M; Paul S; Parker CJ; Stenehjem DD; Rodgers GM
    J Oncol Pharm Pract; 2019 Apr; 25(3):719-723. PubMed ID: 29357781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
    Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
    Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
    [No Abstract]   [Full Text] [Related]  

  • 14. Emperipolesis in a patient receiving romiplostim.
    Cooper N; Bain BJ
    Am J Hematol; 2016 Jan; 91(1):166. PubMed ID: 26407183
    [No Abstract]   [Full Text] [Related]  

  • 15. [Management of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia, ITP)].
    Kashiwagi H; Tomiyama Y
    Rinsho Ketsueki; 2014 Oct; 55(10):2087-94. PubMed ID: 25297775
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim.
    Meletis J; Katsandris A; Raptis SD; Mantzourani M
    Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia.
    Roumier M; Le Burel S; Audia S; Chauchet A; Gousseff M; Hamidou M; Liferman F; Moulis G; Lioger B; Galicier L; Ebbo M; London J; Poutrel S; Terriou L; Zarrouk V; Michel M; Godeau B; Mahevas M
    Am J Hematol; 2021 Feb; 96(2):E43-E46. PubMed ID: 33125750
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine.
    Okazuka K; Masuko M; Matsuo Y; Miyakoshi S; Tanaka T; Kozakai T; Kobayashi H; Fuse K; Shibasaki Y; Moriyama M; Takizawa J; Fuse I; Toba K; Furukawa T
    Intern Med; 2013; 52(11):1239-42. PubMed ID: 23728563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Romplostim in the treatment of immune thrombocytopenic purpura at a tertiary hospital].
    Riu Viladoms G; Creus Baró N; Estefanell Tejero A; Ribas Sala J
    Farm Hosp; 2012; 36(5):434-7. PubMed ID: 22871365
    [No Abstract]   [Full Text] [Related]  

  • 20. Romiplostim dose response in patients with immune thrombocytopenia.
    Perez-Ruixo JJ; Green B; Doshi S; Wang YM; Mould DR
    J Clin Pharmacol; 2012 Oct; 52(10):1540-51. PubMed ID: 22167563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.